DaVita Inc. (DVA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers DaVita Inc.'s unaudited financial results for the quarterly period ended June 30, 2026. DaVita is a leading provider of kidney dialysis services in the United States, operating through its U.S. dialysis segment and ancillary services (including Integrated Kidney Care and international operations). As of July 31, 2026, the company had approximately 63.8 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $3,554.1 | $3,379.5 | $6,969.6 | $6,603.1 |
| Operating Income | $579.0 | $537.8 | $1,060.9 | $976.8 |
| Net Income (Attributable to DaVita) | $265.4 | $199.3 | $462.9 | $362.3 |
| Diluted EPS | $4.02 | $2.58 | $6.86 | $4.57 |
| Operating Cash Flow (YTD) | $810.9 | $504.2 | - | - |
| Free Cash Flow (YTD) | $396.0 | $112.0 | - | - |
| Total Debt (Principal) | $10,847.5 | - | - | - |
| Cash & Equivalents | $669.0 | - | - | - |
Note: Debt and Cash figures represent balances as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 5.2% year-over-year (Q2) and 5.6% year-over-year (YTD). U.S. dialysis revenues grew 3.8% YTD, driven by Medicare base rate increases and higher patient counts. Ancillary services revenues grew 17.0% YTD.
- Profitability: Net income attributable to DaVita Inc. increased 33.1% in Q2 and 27.8% YTD compared to 2025. Operating margins improved due to productivity gains and lower patient care costs per treatment in Q2.
- Cost Management: Patient care costs per treatment decreased 1.0% in Q2 2026 compared to Q1 2026, driven by lower labor costs and pharmaceutical expenses. However, YTD patient care costs per treatment increased 3.2% compared to 2025 due to wage inflation and insurance costs.
- Cash Flow: Operating cash flow improved significantly to $810.9 million YTD 2026 from $504.2 million YTD 2025, aided by favorable working capital changes and the absence of cybersecurity incident-related collection disruptions seen in 2025.
- Debt Activity: The company incurred $2.0 million in debt extinguishment and modification costs in Q2 2026 related to an amendment of its Term Loan B-2, which added $500 million in incremental principal.
Outlook, Risks, and Unusual Items
- Guidance & Outlook: Management expects productivity improvements to continue. The company plans to broadly offer expanded hemodialysis (expanded HD) therapies in coming quarters. No specific numerical guidance for the full year was provided in this text, but management anticipates continued pressure from labor costs and inflation.
- Unusual Items: The prior year (2025) included approximately $13.5 million in cybersecurity incident-related charges (patient care and G&A) which are excluded from 2026 results. The 2026 period included $2.0 million in debt modification costs.
- Risks & Contingencies:
- Regulatory: Ongoing investigations by the U.S. Attorney's Office (New Jersey and Pennsylvania), California Department of Insurance, and the FTC regarding antitrust and compliance matters. Accruals for these matters are currently immaterial.
- Reimbursement: Risks related to potential reductions in government payment rates (Medicare/Medicaid) and changes in the Affordable Care Act premium tax credits affecting commercial mix.
- Operational: Labor market volatility, union organizing activities, and supply chain disruptions remain key risks.
- Subsequent Events: On July 20, 2026, the company closed an acquisition of a noncontrolling minority interest in Elara Caring for $200 million. On July 7, 2026, the company entered into forward interest rate cap agreements with a notional amount of $750 million.
Investor Verification Checklist
- Debt Structure: Verify the impact of the $500 million Term Loan B-2 increment and the $2.0 million modification costs on future interest expense and covenant compliance.
- Payor Mix: Monitor the trend in commercial vs. government payor mix, as the expiration of enhanced premium tax credits in late 2025 has adversely impacted commercial enrollment.
- Legal Exposure: Review the status of the 2020 U.S. Attorney investigations and the 2021 Antitrust class action (class certification denied in June 2026) for potential future liabilities.
- Capital Allocation: Confirm the remaining $1.373 billion available for share repurchases and the company's commitment to returning capital versus funding growth initiatives like the Elara Caring investment.
- IKC Performance: Assess the sustainability of the Integrated Kidney Care (IKC) segment's turnaround, which moved from an operating loss in Q1 2026 to a $40 million operating profit in Q2 2026.